팔리페리돈 장기지속형주사제의 약물 순응도와 치료 효과
The Drug Adherence and Treatment Effect of the Paliperidone Long Acting Injection
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objectives ZZThe aim of this study was to examine the drug adherence and treatment effect of the paliperidone long acting injection (LAI) in patients with schizophrenia or other psychotic disorders. MethodsZZWe reviewed the medical charts of patients who were prescribed paliperidone LAI from January 2010 to April 2014. Date of each injection, last observation, and first admission after use of the drug were obtained. Kaplan-Meier survival analysis was used for calculation of drug adherence. The dose of paliperidone LAI, concurrent oral antipsychotics, and anticholinergic agent was also obtained. Antipsychotics dose was calculated as olanzapine equivalent dose. ResultsZZThe drug adherence of the paliperidone LAI on day 365 was 65%. The reasons for all cause discontinuation were follow-up loss, no effect, poor insight, rejection, extrapyramidal symptom, pain, etc. A total dose of 9.1 mg of oral antipsychotics was decreased, while the dose of anticholinergic agent was increased. ConclusionZZThe drug adherence of the paliperidone LAI was 65%, which was concordant with previous studies. The dose of concurrent oral antipsychotics was increased, while the dose of anticholinergic agent was decreased.
Abstract
Objectives ZZThe aim of this study was to examine the drug adherence and treatment effect of the paliperidone long acting injection (LAI) in patients with schizophrenia or other psychotic disorders. MethodsZZWe reviewed the medical charts of patients who were prescribed paliperidone LAI from January 2010 to April 2014. Date of each injection, last observation, and first admission after use of the drug were obtained. Kaplan-Meier survival analysis was used for calculation of drug adherence. The dose of paliperidone LAI, concurrent oral antipsychotics, and anticholinergic agent was also obtained. Antipsychotics dose was calculated as olanzapine equivalent dose. ResultsZZThe drug adherence of the paliperidone LAI on day 365 was 65%. The reasons for all cause discontinuation were follow-up loss, no effect, poor insight, rejection, extrapyramidal symptom, pain, etc. A total dose of 9.1 mg of oral antipsychotics was decreased, while the dose of anticholinergic agent was increased. ConclusionZZThe drug adherence of the paliperidone LAI was 65%, which was concordant with previous studies. The dose of concurrent oral antipsychotics was increased, while the dose of anticholinergic agent was decreased.
참고문헌 (26)
- Fatemi SH, "The neurodevelopmental hypothesis of schizophrenia, revisited", Schizophr Bull, 35, pp.528~548 (2009)
- Lieberman JA, "Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia", CNS Spectr, 12(3 Suppl 4), pp.1~13 (2007)
- Velligan DI, "Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines", J Psychiatr Pract, 16, pp.306~324 (2010)
- Lambert M, "Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis", J Clin Psychopharmacol, 30, pp.565~572 (2010)
- Velligan DI, "The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness", J Clin Psychiatry, 70(Suppl 4), pp.1~46 (2009)
- Bhanji NH, "A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia", Eur Neuropsychopharmacol, 14, pp.87~92 (2004)
- Kishimoto T, "Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
- Fleischhacker WW, "Second-generation antipsychotic long-acting injections:systematic review", Br J Psychiatry Suppl, 52, pp.S29~S36 (2009)
- Hill CL, "Four-week iloperidone depot injectable:safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder", Proceedings of the 161st Annual Meeting of American Psychiatric Association: New Research Abstracts, 169(NR4-022) (2008), APA
- Citrome L, "Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic", Int J Clin Pract, 63, pp.140~150 (2009)
- Pandina GJ, "A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia", J Clin Psychopharmacol, 30, pp.235~244 (2010)
- Gopal S, "Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study", Int Clin Psychopharmacol, 25, pp.247~256 (2010)
- Kramer M, "Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study", Int J Neuropsychopharmacol, 13, pp.635~647 (2010)
- Hough D, "Paliperidone palmitate maintenance treatment in delaying the time-torelapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study", Schizophr Res, 116, pp.107~117 (2010)
- Alphs L, "Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial", Ann Gen Psychiatry, 10, pp.12~ (2011)
- Lee JS, "Efficacy and tolerability of paliperidone palmitate in asian patients with schizophrenia", Korean J Psychopharmacol, 22(Suppl 2), pp.S49~S56 (2011)
- 김보라미, "한국의 비순응 조현병 환자에서 경구용 비정형 항정신병 약물 대비 항정신병 장기지속형 주사제 Paliperidone Palmitate의 비용-효용분석", 대한정신약물학회지, 23(1), pp.17~27 (2012), 대한정신약물학회
- Gardner DM, "International consensus study of antipsychotic dosing", Am J Psychiatry, 167, pp.686~693 (2010)
- Attard A, "Paliperidone palmitate long-acting injection--prospective year-long follow-up of use in clinical practice", Acta Psychiatr Scand, 130, pp.46~51 (2014)
- Taylor DM, "Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome", Int J Neuropsychopharmacol, 9, pp.685~694 (2006)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Moritz S, "Nonadherence to antipsychotics:the role of positive attitudes towards positive symptoms", Eur Neuropsychopharmacol, 24, pp.1745~1752 (2014)
- Gopal S, "Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies", Neuropsychiatr Dis Treat, 9, pp.1381~1392 (2013)
- Leo RJ, "Atypical antipsychotic use in the treatment of psychosis in primary Care", Prim Care Companion J Clin Psychiatry, 2, pp.194~204 (2000)
- Kim YS, "Principle and practice of long-acting injectable antipsychotics", pp.256~262 (2012), Seoul National University Press
- Gentile S, "Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review", Pharmacotherapy, 33, pp.1087~1106 (2013)